Korean J Hematol 2009; 44(2):
Published online June 30, 2009
https://doi.org/10.5045/kjh.2009.44.2.108
© The Korean Society of Hematology
배수영 김여경 윤주영 이성지 김대은 유성윤 홍승덕 조대호 황준일 배우균 심현정 안재숙 양덕환 조상희 이제중 정익주 김형준
전남대학교 의과대학 내과학교실,
화순전남대학교병원 조혈계질환 유전체 연구센터
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea. (Korean J Hematol 2009;44:108-112.)
Keywords Immune thrombocytopenic purpura, Rituximab, Toxic epidermal necrolysis
Korean J Hematol 2009; 44(2): 108-112
Published online June 30, 2009 https://doi.org/10.5045/kjh.2009.44.2.108
Copyright © The Korean Society of Hematology.
배수영 김여경 윤주영 이성지 김대은 유성윤 홍승덕 조대호 황준일 배우균 심현정 안재숙 양덕환 조상희 이제중 정익주 김형준
전남대학교 의과대학 내과학교실,
화순전남대학교병원 조혈계질환 유전체 연구센터
Soo Young Bae, Yeo Kyeoung Kim, Joo Young Yoon, Sung Ji Lee, Dae Eun Kim, Sung Yoon Rew, Seung Dok Hong, Dae Ho Jo, Joon Il Hwang, Woo Kyun Bae, Hyun Jeong Shim, Jae Sook Ahn, Deok Hwan Yang, Sang Hee Cho, Je Jung Lee, Ik Joo Chung, Hyeoung Joon Kim
Department of Internal Medicine, Chonnam National University Medical School, Gwangju
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Korea
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea. (Korean J Hematol 2009;44:108-112.)
Keywords: Immune thrombocytopenic purpura, Rituximab, Toxic epidermal necrolysis
Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50Yoon Seok Choi
Blood Res 2020; 55(S1): S58-S62